3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: A cross-sectional quality-of-life survey

References

• Galalae RM, Martinez A, Mate T, Mitchell C, Edmundsun G, Nuernberg N, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 1048–55
   PubMed Web of Science ®Google Scholar
• Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097–105
   PubMed Web of Science ®Google Scholar
• Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE. Prostate cancer radiotherapy dose response: An update of the Fox Chase experience. J Urol 2004; 171: 1132–6
   Google Scholar
• Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002; 53: 1111–6
   PubMed Web of Science ®Google Scholar
• Aebersold DM, Isaak B, Thalmann G, Behrensmeier F, Kolotas C, Kranzbuhler H, et al. Applicability and dosimetric impact of ultrasound-based preplanning in high-dose rate brachytherapy of prostate cancer. Strahlenther Onkol 2004; 180: 351–7
   Google Scholar
• Martin T, Baltas D, Kurek R, Roddiger S, Kontova M, Anagnostopoulos G, et al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer: A pilot study. Strahlenther Onkol 2004; 180: 225–32
   PubMed Web of Science ®Google Scholar
• Wahlgren T, Nilsson S, Ryberg M, Lennernas B, Brandberg Y. Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localised prostate cancer: A prospective assessment of acute and late treatment toxicity. Acta Oncol 2005; 44: 633–43
   PubMed Web of Science ®Google Scholar
• Penson DF, Litwin MS, Aaronson NK. Health related quality of life in men with prostate cancer. J Urol 2003; 169: 1653–61
   PubMed Web of Science ®Google Scholar
• Egawa S, Shimura S, Irie A, Kitano M, Nishiguchi I, Kuwao S, et al. Toxicity and health-related quality of life during and after high-dose rate brachytherapy followed by external beam radiotherapy for prostate cancer. Jpn J Clin Oncol 2001; 31: 541–7
   PubMed Web of Science ®Google Scholar
• Galalae RM, Loch T, Riemer B, Rhezak P, Kuchler T, Kimmig B, et al. Health-related quality of life measurement in long-term survivors and outcome following radical radiotherapy for localized prostate cancer. Strahlenther Onkol 2004; 180: 582–9
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Reddy CA, Klein EA, Willoughby TR. Short-course intensity modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001; 51: 988–93
   PubMed Web of Science ®Google Scholar
• Little DJ, Kuban DA, Levy LB, Zagars GK, Pollack A. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose escalastion study. Urology 2003; 62: 707–13
   PubMedGoogle Scholar
• Wahlgren T, Brandberg Y, Häggarth L, Hellström M, Nilsson S. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with 192Ir brachytherapy: A prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25. Int J Radiat Oncol Biol Phys 2004; 60: 51–9
   PubMed Web of Science ®Google Scholar
• Mc Neal JF. The zonal anatomy of the prostate. Prostate 1981; 2: 35–49
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76
   PubMed Web of Science ®Google Scholar
• Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 2001; 37: 1345–51
   PubMed Web of Science ®Google Scholar
• Aaronson NK, van Andel G. An international field study of the reliability and validity of the QLQ-C30 and a disease-specific questionnaire module (QLQ-PR25) for assessing quality of life of patients with prostate cancer. European Organization for Research and Treatment of Cancer study protocol 15011. Brussels: 2002.
   Google Scholar
• Fayers PM, Aaronson NK, Bjordal K, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual. 3rd ed. European Organisation for Research and Treatment of Cancer. Brussels: 2001.
   Google Scholar
• Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Using reference data on quality of life – the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3). Eur J Cancer 1998; 34: 1381–9
   PubMed Web of Science ®Google Scholar
• Gulbrandsen N, Hjermstad MJ, Wisloff F, Nordic Myeloma Study Group. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 2004; 72: 172–80
   PubMed Web of Science ®Google Scholar
• Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004; 43: 316–81
   PubMed Web of Science ®Google Scholar
• Vordermark D, Flentje M. Planning target volume definition in dose-escalation studies. Front Radiat Ther Oncol 2002; 36: 16–24
   Google Scholar
• Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139–44
   PubMed Web of Science ®Google Scholar
• Ott C, Fulton MK. Osteoporosis risk and interest in strength training in men receiving androgen ablation therapy for locally advanced prostate cancer. J Am Acad Nurse Pract 2005; 17: 113–22
   Google Scholar
• Zelefsky MJ, Cowen D, Fuks Z, Venkatraman ES, Cowen DM, Levegrun S, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999; 85: 2460–8
   PubMed Web of Science ®Google Scholar
• Hoskin PJ. High dose rate brachytherapy boost treatment in radical radiotherapy for prostate cancer. Radiother Oncol 2000; 57: 285–8
   Google Scholar
• Boehmer D. Multi-center phase III trial on combined interstitial high-dose-rate brachytherapy plus external-beam radiotherapy versus external-beam radiotherapy alone in patients with locally advanced prostate cancer. Berlin: 2006.
   Google Scholar